Tirzepatide is a synthetic peptide drug that belongs to a newer class of medications called dual GIP/GLP-1 receptor agonists. It activates both the GLP-1 (glucagon-like peptide-1) receptor — like Semaglutide — and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action enhances insulin secretion when blood sugar is high, suppresses glucagon release, slows gastric emptying, and reduces appetite, while also improving fat metabolism and insulin sensitivity.
Tirzepatide is primarily used for type 2 diabetes treatment and is being adopted off-label for weight loss, with results often surpassing those seen with Semaglutide. Clinical trials have shown impressive outcomes, including very significant reductions in HbA1c and body weight (some participants losing more than 20% of their starting weight). The combination of GLP-1 and GIP activation is thought to create a more powerful effect on both glucose control and appetite suppression.
